GlassScriptPhysician profile
Jae Y Kim
NPI 1023147014
$18,737.28
in general payments reported to CMS, 2019-2025
12 companies · $4,438 in 2025
The $4,438 reported for 2025 was more than what 81% of Thoracic Surgery (Cardiothoracic Vascular Surgery) providers received nationally (typical 2025 total: $796).
See the full distribution for Thoracic Surgery (Cardiothoracic Vascular Surgery)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.08 · 2020: $2,365 · 2021: $5,432 · 2022: $3,657 · 2023: $2,639 · 2024: $163 · 2025: $4,438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,500 · Consulting Fee: $2,148 · Travel and Lodging: $1,757 · Food and Beverage: $534 · Honoraria: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,500.00 |
| Consulting Fee | $2,148.00 |
| Travel and Lodging | $1,757.34 |
| Food and Beverage | $534.43 |
| Honoraria | $300.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $9,042.86 | 2019-2025 | Da Vinci Surgical System |
| Astrazeneca Pharmaceuticals LP | $6,085.34 | 2020-2024 | Imfinzi, Tagrisso |
| Genzyme Corporation | $2,706.00 | 2022 | |
| Ethicon INC. | $485.96 | 2020 | |
| Vascular Technology, INC. | $300.00 | 2023 | |
| Merck Sharp & Dohme LLC | $28.76 | 2024 | Keytruda |
| Janssen Biotech, INC. | $22.76 | 2024 | Rybrevant |
| Janssen Pharmaceuticals, INC | $19.66 | 2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $16.91 | 2024 | Opdivo |
| Siemens Medical Solutions USA, INC. | $15.00 | 2022 | |
| Eisai INC. | $14.03 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jae Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.